
Semaxanib
CAS No. 194413-58-6
Semaxanib ( SU5416 )
Catalog No. M13045 CAS No. 194413-58-6
Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 102 | In Stock |
![]() ![]() |
10MG | 178 | In Stock |
![]() ![]() |
25MG | 314 | In Stock |
![]() ![]() |
50MG | 538 | In Stock |
![]() ![]() |
100MG | 659 | In Stock |
![]() ![]() |
200MG | 897 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameSemaxanib
-
NoteResearch use only, not for human use.
-
Brief DescriptionSemaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM.
-
DescriptionSemaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM, 20-fold more selective for VEGFR than PDGFRβ, lack of activity against EGFR, InsR and FGFR. Phase 3.
-
In Vitro——
-
In Vivo——
-
SynonymsSU5416
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorVEGFR2/Flk1
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number194413-58-6
-
Formula Weight238.28
-
Molecular FormulaC15H14N2O
-
Purity>98% (HPLC)
-
SolubilityEthanol: 2 mg/mL (8.39 mM); DMSO: 22 mg/mL (92.32 mM)
-
SMILESCC1=CC(=C(N1)/C=C\2/C3=CC=CC=C3NC2=O)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Fong TA, et al. Y Res, 1999, 59(1), 99-106.
molnova catalog



related products
-
8-O-Acetylshanzhisid...
8-O-Acetylshanzhiside methylester has potential against cerebral ischemic injury, and its protective effect on oxygen-glucose deprivation-induced injury might be due to the suppression of intracellular Ca2+ elevation and caspase-3 activity.
-
UNC0064-12
2,4-Pyrimidinediamine with linker is a patent compound in WO2013055780A1.
-
Vatalanib free base
A potent, orally available class III receptor tyrosine kinases inhibitor with IC50 of <1 uM for VEGFR, Flt-1, KDR and PDGFRβ.